8-K ·Filed Jun 16, 2026

ELUT

ELUTIA INC.
NEUTRAL
Impact 3/10
Horizonmonths Processed3mo ago SEC0001104659-26-074660
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

The 3M share increase provides headroom for future equity compensation but does not represent immediate dilution. Monitor future 10-Q filings for actual share issuance under the plan. No near-term catalyst from this filing.

DirectionNeutral
Confidencehigh
Horizonmonths
Final — all horizons settled through T+60d
ELUT ▼ -18.30% at T+60d
NEUTRAL call ✗ call lost -18.30% · α vs SPY -21.45% · entry $0.9914 → $0.8100
Entry anchored
Jun 16, 03:59 PM ET
via exchange tick
T+1d
+6.92%
call +6.92% · α +6.14%
$1.06
settled 4mo ago
T+5d
-1.04%
call -1.04% · α +0.00%
$0.9811
settled 3mo ago
T+20d
-4.18%
call -4.18% · α -5.49%
$0.9500
settled 3mo ago
T+60d
-18.30%
call -18.30% · α -21.45%
$0.8100
settled 21d ago

Price Chart

Loading chart...

Executive Summary

Elutia Inc. filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders, where shareholders approved an amendment to the 2020 Incentive Award Plan, increasing authorized shares by 3,000,000. All director nominees were elected, and advisory say-on-pay was approved with an annual frequency recommendation. This is a routine governance filing with no material financial impact.

Key Facts

  • Shareholders approved the First Amendment to the 2020 Incentive Award Plan, increasing authorized shares by 3,000,000 shares of Class A common stock.
  • Annual meeting had 34,041,545 shares present (77.0% of outstanding) as of April 17, 2026 record date.
  • David Colpman and Kevin Rakin were elected as Class III directors.
  • PricewaterhouseCoopers LLP ratified as independent auditor for FY2026.
  • Advisory say-on-pay approved with 25,617,864 votes for; annual frequency recommended.

Financial Impact

Potential dilution from up to 3,000,000 additional shares authorized for equity awards; no immediate financial impact.

dilution

Risk Factors

  • Potential dilution from future equity awards under the expanded plan.
  • No material change to business fundamentals or financial outlook.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-074660
Document: 0001104659-26-074660-index-headers.html0001104659-26-074660
Document: 0001104659-26-074660-index.html0001104659-26-074660
Document: 0001104659-26-074660.txt0001104659-26-074660
4 reports for ELUT
Performance horizon
Filters
Rows
Reports for ELUT — sortable, filterable
TypeNow
Jul 31, 2026
9w ago
Press Release
NEUTRAL ★ 2/10
$0.8568 $0.8800▲ +2.71%▼ −0.28%$0.7787 (−9.12%)
Jun 16, 2026
15w ago
8-K
NEUTRAL ★ 3/10
$0.9914 $0.9500▼ −4.18%▼ −5.49%$0.7787 (−21.45%)
May 14, 2026
20w ago
8-K
NEUTRAL ★ 5/10
$1.03 $0.9690▼ −5.92%▼ −8.04%$0.7787 (−24.40%)
Mar 11, 2026
29w ago
8-K
MIXED ★ 7/10
$1.15 $1.13▼ −1.74%▼ −3.71%$0.7787 (−32.29%)
Showing 4 of 4

US Market Status

Market Closed — Opens Mon (38h 37m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access